Marinus Pharmaceuticals Inc

-0.07 (-1.45%)
Products, Expansion, Regulatory

Marinus Pharmaceuticals Expands Enrollment Criteria To Support Recruitment In Phase 3 Raise Trial In Refractory Status Epilepticus

Published: 06/08/2022 13:21 GMT
Marinus Pharmaceuticals Inc (MRNS) - Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 Raise Trial in Refractory Status Epilepticus.
Marinus Pharmaceuticals Inc - Expects That Vast Majority of Sites Will Adopt Protocol Updates by Middle of Q3 of 2022.
Marinus Pharmaceuticals Inc - Targeting 65-75 Sites Globally and Continues to Expect Topline Data in Second Half of 2023.
Marinus Pharmaceuticals-looks to Initiate Site Activations in Canada in Q3 Targeting 10 New Sites, Evaluating Further Expansion Into Israel, Australia.